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Abstract
Background: According to EULAR recommendations, biologic DMARDs (bDMARDs) such as tumor necrosis factor
inhibitor, tocilizumab (TCZ), and abatacept (ABT) are in parallel when prescribing to rheumatoid arthritis (RA)
patients who have shown insufficient response to conventional synthetic DMARDs. However, most prediction
studies of therapeutic response to bDMARDs using gene expression profiles were focused on a single bDMARD,
and consideration of the results from the perspective of RA pathophysiology was insufficient. The aim of this study
was to identify the specific molecular biological features predicting the therapeutic outcomes of three bDMARDs
(infliximab [IFX], TCZ, and ABT) by studying blood gene expression signatures of patients before biologic treatment
in a unified test platform.
Methods: RA patients who responded inadequately to methotrexate and were later commenced on any one of IFX
(n = 140), TCZ (n = 38), or ABT (n = 31) as their first biologic between May 2007 and November 2011 were enrolled.
Whole-blood gene expression data were obtained before biologic administration. Patients were categorized into
remission (REM) and nonremission (NON-REM) groups according to CDAI at 6 months of biologic therapy. We
employed Gene Set Enrichment Analysis (GSEA) to identify functional gene sets differentially expressed between
these two groups for each biologic. Then, we compiled “signature scores” for these gene sets, and the prediction
performances were assessed.
Results: GSEA showed that inflammasome genes were significantly upregulated with IFX in the NON-REM group
compared with the REM group. With TCZ in the REM group, B-cell-specifically expressed genes were upregulated.
RNA elongation, apoptosis-related, and NK-cell-specifically expressed genes were upregulated with ABT in the
NON-REM group. Logistic regression analyses showed that “signature scores” of inflammasomes, B-cell-specifically
expressed, and NK-cell-specifically expressed genes were significant, independently predictive factors for treatment
outcome with IFX, TCZ, and ABT, respectively. The AUCs of ROC curves of these signature scores were 0.637, 0.796,
and 0.768 for IFX, TCZ, and ABT, respectively.
Conclusions: We have identified original gene expression predictive signatures uniquely underlying the therapeutic
effects of IFX, TCZ, and ABT. This is, to our knowledge, the first attempt to predict therapeutic effects of three drugs
concomitantly using a unified gene expression test platform.
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Background
Methotrexate (MTX) and biologic disease-modifying an-
tirheumatic drugs (bDMARDs) have brought therapeutic
success to most but not all patients with rheumatoid
arthritis (RA). Optimization of treatment for individual
patients and development of novel therapies are eagerly
anticipated. A good effort regarding the former is to es-
tablish a standard methodology to determine which
bDMARDs to prescribe. As the molecular target of
each bDMARD is distinct, each effective treatment
should link to changes in one or several particular bio-
logical processes that are ultimately manifested in a dis-
ease state. Despite this understanding and supporting
evidence, current concepts of prescription of bDMARDs
are unsatisfactory. According to the European League
Against Rheumatism (EULAR) recommendations, tumor
necrosis factor (TNF) inhibitor, tocilizumab (TCZ),
and abatacept (ABT) are in parallel when determining
first biologics to use for patients with RA who have
shown inadequate response to conventional synthetic
DMARDs (csDMARDs) [1]. Development of a method-
ology to determine effective therapy using bDMARDs is
definitely essential.
Most prediction studies of therapeutic response to
bDMARDs using gene expression profiles of blood sam-
ples have been focused on a single biologic [2–9], and to
date no report of multiple drugs studied in parallel is
available. Furthermore, study designs have varied, thus
rendering translational studies very challenging.
Difficulty in reproducing gene expression studies has
also plagued this area of study, partly due to nonunifor-
mities of study design but also to data processing itself
[10]. Instead of incorporating existing biological know-
ledge, analysis rarely extends beyond the individual gene
level to explain how the biomarker findings are associ-
ated with modes of action related to targeted therapies
for RA. Furthermore, to establish a robust model using
gene expression, it is essential to interpret the results as
effects of a collective network of related genes rather
than of the gene per se. In this context, Gene Set Enrich-
ment Analysis (GSEA) [11], which was shown to detect
differentially expressed functional gene sets, should be a
promising approach.
In this study, to identify therapeutic efficacy markers
of three bDMARDs (infliximab [IFX], TCZ, and ABT)
targeted at different molecules, we took the aforemen-
tioned problems into consideration. We designed a
unified test platform in which the subject recruitment
criteria, treatment response evaluation, and assay sys-
tem platform are well defined. GSEA is employed to
identify and annotate the gene signatures associated
with each biologic. The prediction performance, bio-
logical interpretation, and utility of each gene signa-
ture are presented.
Methods
Patients and evaluation of effectiveness
The diagnosis of RA in the present study was based on
the 1987 revised criteria of the American College of
Rheumatology (ACR) for the classification of RA or on
the 2010 ACR/EULAR classification criteria. We en-
rolled patients with RA who responded inadequately to
MTX (≥6 mg/week) and were commenced on any one
of IFX, TCZ (2008), or ABT (2010) as their first biologic
between May 2007 and November 2011 at Keio Univer-
sity Hospital and Saitama Medical University Saitama
Medical Center. Biologics were administered according
to the guidelines set by the Japan College of Rheumatology
(http://www.ryumachi-jp.com/guideline.html [in Japanese]).
Therapeutic outcomes were defined as achieving remis-
sion (REM; defined as clinical disease activity index
[CDAI] ≤2.8) or not achieving remission (NON-REM)
on the basis of CDAI at 6 months of biologic therapy,
since other disease activity indexes such as the disease
activity score in 28 joints (DAS28) incorporate inflamma-
tory factors such as C-reactive protein or erythrocyte sedi-
mentation rate (ESR), which may overestimate the efficacy
of TCZ [12, 13]. Patients who discontinued biologic therapy
by 6 months due to insufficient effects (n = 5) or adverse
events (n = 1) were classified as NON-REM (Additional file
1). The CDAI of all six cases were >2.8 as determined using
the last observation carried forward (LOCF) method. Writ-
ten informed consent was obtained from all patients in ac-
cordance with the Declaration of Helsinki protocol, and the
study protocol was approved by the institutional review
boards at Keio University and Saitama Medical University.
RNA extraction
Before administration of a biologic agent, blood samples
were collected in PAXgene Blood RNA tubes [14]
(PreAnalytiX, Hombrechtikon, Switzerland). Total RNAs
were extracted using PAXgene Blood RNA kits (PreAn-
alytiX) following the manufacturer’s instructions. Total
RNA quantity and quality were determined using a Nano-
Drop 1000 spectrophotometer (NanoDrop Products/
Thermo Fisher Scientific, Wilmington, DE, USA) and an
Agilent 2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA, USA). All RNA samples fulfilled both of the
following criteria: RNA integrity >6.5 and optical density
at 260/280 nm >1.6.
Gene expression measurements
Cyanine 3-labeled complementary RNAs (cRNAs) were
synthesized using QuickAmp Labeling Kits (Agilent
Technologies). The cRNAs were hybridized at 65 °C for
17 h to Whole Human Genome 44 K Microarrays (de-
sign ID 014850; Agilent Technologies). After being
washed, the microarrays were scanned using an Agilent
DNA microarray scanner (Agilent Technologies).
Nakamura et al. Arthritis Research & Therapy  (2016) 18:159 Page 2 of 12
Intensity values of each scanned feature were quantified
using Agilent Feature Extraction software (Agilent
Technologies). The raw microarray data are deposited
in the National Center for Biotechnology Information
Gene Expression Omnibus database under accession
number [GSE78068]. We applied rank-based quantile
normalization to the raw signal data using R software
version 3.0.2. Next, probes were filtered based on preex-
isting annotation with gene symbol and signal intensity
(called “present” in more than 50 samples according
to GeneSpring software [Agilent Technologies]). For
genes with more than one probe, we adopted the
probe that had the highest signal intensity. The final
number of probes used for subsequent analysis was
14,718.
GSEA
We employed GSEA to study the molecular biological
features of the REM and NON-REM groups associated
with each biologic therapy. GSEA is a computational
method that determines whether a set of genes defined a
priori shows statistically significant, concordant differ-
ences between two biological states [11].
We used GSEA v2.1.0, and input data comprised three
sets of data matrices (i.e., 14,718 genes × 140 samples
[IFX], 14,718 genes × 38 samples [TCZ], and 14,718
genes × 31 samples [ABT]). Two lists of gene sets were
used as sets of genes defined a priori (i.e., Reactome
gene sets in the Molecular Signatures Database [11]),
containing 674 pathways and integrated lists of blood
cell type-specific expressed gene sets published by
Watkins et al. [15] and Allantaz et al. [16]. The inte-
grated lists have 16 blood cell type-specific expressed
gene sets (Additional file 2). Permutation type was set as
“phenotype,” and the number of permutations was 1000.
The population gene set for analysis was 14,718, and the
metrics for ranking genes were the signal-to-noise ratios.
Gene set size filters were in default settings, where the
minimum was 15 and the maximum was 500. Gene
sets with a nominal p value <0.05 and a false discovery
rate <0.1 were considered significant. Then, we defined
“core genes” as the subset of genes that contributed
most to the GSEA enrichment score.
Real-time quantitative reverse transcription polymerase
chain reaction
Real-time quantitative reverse transcription-polymerase
chain reactions (qRT-PCRs) were performed for 11–13
samples of each biologic where total RNAs were adequate.
Genes measured were APP, AIM2, NLRC4, MEFV, and
BCL2L1 for inflammasomes (signature of IFX); PLEKHG1,
AFF3, FCER2, UGT8, and CD22 for specific CD19
(signature of TCZ); and BNC2, CD160, PDGFRB, LIM2,
and KIR3DL2 for specific CD56 (signature of ABT). We
designed custom RT2 Profiler PCR Arrays (QIAGEN, Val-
encia, CA, USA), and the assay was performed according
to the manufacturer’s instructions. Essentially, 500 ng of
total RNA of each sample was used to synthesize
complementary DNA using the RT2 HT First Strand Kit
(QIAGEN). qRT-PCR was performed using the Applied
Biosystems 7500 Fast Dx Real-Time PCR System (Thermo
Fisher Scientific, Foster City, CA, USA). The relative ex-
pression of each gene was quantified by measuring cycle
threshold (Ct) values and normalizing against GUSB.
Calculation of signature score
The scoring system we used, which is clinically applic-
able to each patient, is shown in Additional file 3.
Briefly, each core gene that belonged to a target gene set
was standardized using a z-score transformation based
on all 209 patients’ data, and then the average of z-
scores of all core genes was defined as the “signature
score” of the gene set for each patient.
ROC analysis
ROC (receiver operating characteristic) analysis was
conducted using the signature score compared with
REM versus NON-REM category, and AUC of the
ROC curve was determined. We applied the same
sample group that was used to construct the gene
signature. NON-REM was defined as “positive.” The
sensitivity, specificity, positive predictive value (PPV),
and negative predictive value were determined at the
optimal cutoff value (threshold) from the ROC curve.
Analysis was performed using R software version 3.0.2.
Statistical analysis
The CDAI of six samples where administration was
terminated before 6 months (see "Patients and evalu-
ation of effectiveness" section) was estimated using the
LOCF method. The Kruskal-Wallis test, Wilcoxon’s rank-
sum test, or Student’s t test was performed for numerical
variables. For categorical variables, Fisher’s exact test was
conducted. The associations between CDAI remission at
6 months of biologic therapy and signature scores were
evaluated using univariate and multivariate logistic regres-
sion analyses (Firth’s penalized likelihood method [17]).
For multivariate analyses, we adjusted for marginally sig-
nificant (p < 0.1) univariate factors as shown in Additional
file 4. However, owing to the strong correlation with
CDAI (in IFX and TCZ analysis) or concomitant steroid
use (in ABT analysis), we did not adjust 28 tender joint
count (TJC28), 28 swollen joint count (SJC28), patient glo-
bal assessment (PtGA), physician global assessment
(PhGA), DAS28-ESR, and Simplified Disease Activity
Index (SDAI) in IFX analysis; SJC28, DAS28-ESR, and
SDAI in TCZ analysis; or concomitant steroid dose in
ABT analysis.
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In this study, p < 0.05 was considered significant. p
Values derived from these analyses were not adjusted for
multiple testing. All statistical analyses were performed
with R software version 3.0.2.
Results
Baseline clinical characteristics and therapeutic response
to each biologic therapy
There were 140, 38, and 31 cases (total 209) of IFX,
TCZ, and ABT, respectively. The baseline characteristics
of the enrolled patients of three biologic groups are
shown in Table 1. The median age of the patients from
whom the 209 samples were derived was 59 years, and
their disease duration was 3.3 years. Coadministration of
MTX had a median volume of 8 mg, and the median
CDAI was 21.7. Among the biologic agents, the subjects
given ABT were older, and coadministration of MTX
was slightly higher in the IFX group.
Administration was terminated by 6 months for IFX
(n = 1), TCZ (n = 3), and ABT (n = 1) due to insufficient
effect (Additional file 1). In addition, there was an ad-
verse effect case in TCZ. These cases were subsequently
classified as NON-REM. For all 209 cases, 27.3 %
achieved remission at 6 months of biologic therapy
(Fig. 1). The remission rates for IFX, TCZ, and ABT
were 30.0 %, 21.1 %, and 22.6 %, respectively.
Differences in baseline characteristics between the REM
and NON-REM groups are shown in Additional file 4.
Table 1 Patients’ baseline demographics and characteristics
All IFX TCZ ABT p Valuea
Number of patients 209 140 38 31 –
Female sex, n (%) 172 (82.3 %) 113 (80.7 %) 34 (89.5 %) 25 (80.6 %) 0.46626
Age, yr, median (IQR) 59.0 (47.0–66.0) 57.5 (46.0–64.3) 56.0 (44.8–64.0) 67.0 (62.0–74.0) 0.00003
Disease duration, yr, median (IQR) 3.3 (1.1–10.5) 3.3 (1.1–10.3) 4.2 (1.5–9.4) 2.4 (0.5–14.5) 0.86013
Concomitant drug use
Steroid use, n (%) 80 (38.3 %) 56 (40.0 %) 14 (36.8 %) 10 (32.3 %) 0.75247
Steroid dose, mg/day, median (IQR) 0 (0–5.0) 0 (0–5.0) 0 (0–3.0) 0 (0–2.5) 0.34861
MTX dose, mg/week, median (IQR) 8.0 (8.0–8.0) 8.0 (8.0–10.0) 8.0 (6.0–8.0) 8.0 (6.0–8.0) 0.00271
csDMARD useb (except MTX), n (%) 29 (13.9 %) 20 (14.3 %) 5 (13.2 %) 4 (12.9 %) 1.00000
Serological markers
RF positivity, n (%) 154 (74.8 %)c 103 (74.1 %)d 28 (73.7 %) 23 (79.3 %)e 0.88544
RF titer, median (IQR) 55 (15–115)c 53 (14–115)d 54 (17–115) 77 (22–106)e 0.94307
ACPA positivity, n (%) 85 (85.9 %)f 51 (85.0 %)g 13 (100 %)h 21 (80.8 %)i 0.31205
ACPA titer, median (IQR) 85.6 (12.8–100)f 100 (13.3–100)g 83 (42.9–100)h 62.1 (9.8–100)i 0.89773
TJC28, median (IQR) 6.0 (2.0–8.0) 6.0 (2.0–8.3) 6.0 (3.0–8.8) 6.0 (3.0–8.0) 0.68798
SJC28, median (IQR) 6.0 (3.0–11.0) 7.0 (3.8–11.0) 6.0 (4.0–8.0) 5.0 (3.0–8.0) 0.46376
PtGA, mm, median (IQR) 53 (28–72) 52 (27–72) 52 (31–67) 63 (41–73) 0.34811
PhGA, mm, median (IQR) 43 (30–60) 43 (29–63) 43 (33–60) 45 (31–56) 0.91700
CRP, mg/dl, median (IQR) 0.9 (0.4–2.4) 1.0 (0.4–2.6) 0.6 (0.2–2.0) 0.8 (0.4–2.0) 0.19092
ESR, mm/h, median (IQR) 42 (25–69) 45 (28–69) 37 (22–60) 37 (23–74) 0.27517
DAS28-ESR, median (IQR) 5.3 (4.4–6.1) 5.3 (4.4–6.2) 5.1 (4.5–5.8) 5.5 (4.7–6.1) 0.65899
SDAI score, median (IQR) 22.5 (16.2–31.3) 23.2 (15.6–32.2) 22.1 (16.8–28.5) 23.3 (16.8–31.5) 0.96973
CDAI score, median (IQR) 21.7 (14.9–28.9) 21.9 (14.6–29.6) 20.6 (16.4–26.0) 22.8 (15.1–28.5) 0.99430
Abbreviations: IFX infliximab, TCZ tocilizumab, ABT abatacept, IQR interquartile range, MTX methotrexate, csDMARD conventional synthetic disease-modifying anti-
rheumatic drug, RF rheumatoid factor, ACPA anticyclic citrullinated peptide antibodies, TJC28 28 tender joint count, SJC28 28 swollen joint count, PtGA patient glo-
bal assessment, PhGA physician global assessment, CRP C-reactive protein, ESR erythrocyte sedimentation rate, DAS28 disease activity score in 28 joints, SDAI
simplified disease activity index, CDAI clinical disease activity index
aKruskal-Wallis test was used for numerical variables to evaluate the differences between the three drug groups. For categorical variables, Fisher’s exact test was
used. p < 0.05 was considered statistically significant
bIncluding salazosulfapyridine, bucillamine, tacrolimus, D-penicillamine, actarit, and azathioprine
cAvailable for 206 of 209
dAvailable for 139 of 140
eAvailable for 29 of 31
fAvailable for 99 of 209
gAvailable for 60 of 140
hAvailable for 13 of 38
iAvailable for 26 of 31
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There were significant differences in female proportion (p
= 0.034) and concomitant use of csDMARDs besides MTX
(p = 0.016) between the REM and NON-REM groups for
IFX. SJC28, PtGA, PhGA, DAS28-ESR, SDAI, and CDAI
were also significantly higher for IFX in the NON-REM
group. For TCZ, the NON-REM group had a higher
DAS28-ESR (p = 0.045). The duration of disease for the
ABT group was longer in the NON-REM group (p = 0.003).
Baseline gene expression features underlying REM and
NON-REM
We used GSEA to identify the molecular biological features
of the REM and NON-REM groups for each biologic ther-
apy. GSEA is a powerful analytical method to detect mod-
est but coordinated changes in the expression of groups of
functionally related genes. Table 2 summarizes the results
of our GSEA (see also Additional files 5, 6, 7 and 8). In
Reactome gene set analyses, “inflammasomes” in IFX,
“elongation arrest and recovery,” “regulation of apoptosis,”
and “formation of RNA polymerase II (RNA pol II) elong-
ation complex” in ABT showed upregulated expression pat-
terns for NON-REM. In blood cell gene set analysis,
signatures related to B cells, such as “specific CD19” and “B
cell-induced” showed upregulated expression patterns in
the TCZ group for REM. In the ABT group, signatures re-
lated to natural killer (NK) cells, such as “specific CD56”
and “NK cell-induced” showed upregulated expression pat-
terns for NON-REM. The top-performing genes for each
gene set were validated using qRT-PCR (Additional file 9).
Signature scores and therapeutic responses
We compiled “signature scores” based on gene sets identi-
fied using GSEA to evaluate individual gene expression
profiles (see Methods section). Signature scores generated
were able to significantly differentiate REM and NON-
REM (Fig. 2a–h) and thus could serve as a system to pre-
dict each individual’s prospective therapeutic outcome.
We found overlapping genes especially within gene
sets of the TCZ group and gene sets of the ABT group
(Additional files 7 and 8). Correlation analysis of signature
scores of these gene sets indeed confirmed redundancy
(Additional file 10). For the predictive signature of TCZ,
“specific CD19” and “B cell-induced” were consolidated as
“specific CD19” (Pearson’s correlation coefficient 0.99).
For ABT, “elongation arrest and recovery,” “regulation of
apoptosis,” and “formation of RNA pol II elongation com-
plex” were closely related (correlation coefficients 0.77,
0.91, and 0.84, respectively), while “specific CD56” and
“NK cell-induced” also shared a high correlation (correl-
ation coefficient 0.96). We thus subsequently focused on
“elongation arrest and recovery” and “specific CD56.”
Logistic regression analyses of signature score as a uni-
variate independent variable and CDAI remission as a
dependent variable showed that each signature score was
significant (Table 3). In multivariate analyses where the
clinical background of REM and NON-REM (Table 1)
was also taken into account, signature scores remained
significant. We also found that “specific CD56” was more
significant than “elongation arrest and recovery” in ABT,
and thus we concentrated on “specific CD56” in subse-
quent analysis.
Evaluation of prediction performance using signature score
ROC analysis was performed using signature scores
(Fig. 3). The AUCs of signature scores to predict NON-
REM based on CDAI were 0.637 (IFX, signature:
Fig. 1 Disease activity based on CDAI at baseline and 6 months of biologic therapy. CDAI clinical disease activity index, LOCF last observation
carried forward, IFX infliximab, TCZ tocilizumab, ABT abatacept
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inflammasomes), 0.796 (TCZ, signature: specific CD19)
and 0.768 (ABT, signature: specific CD56). Notably, for
all biologic agents, the PPV were high (IFX 83.6 %, TCZ
92.3 %, ABT 94.7 %).
Overview of classification of all 209 samples using
signature scores
A heat map using core genes of inflammasomes, specific
CD19, and specific CD56 revealed that all 209 samples
analyzed in this study could be distributed into 8 groups,
based on the signature score cutoff points determined in
ROC curve analyses (Fig. 4). When these groups were
compared with regard to actual therapeutic outcomes,
the proportions of NON-REM in groups 1 and 2 were
high for all biologics (80–100 %). However, groups 5–7
were composed of patients who achieved remission when
IFX was administered, while group 8 achieved remission
when TCZ or ABT was administered. There were too few
patients to make any observations for groups 3 and 4.
Discussion
Most if not all therapeutic effect prediction studies based
on gene expression research have been focused on single
rather than multiple biologic agents. Variations in the
design of these studies, including recruitment criteria of
subjects, evaluation of treatment response, and of assay
system platform, represent a huge challenge to combin-
ing the studies’ findings in translational studies. There-
fore, it is important to develop a unified test platform
that allows a level and concomitant comparison among
multiple biologic agents and hence anticipation of the
therapeutic outcomes. In this study, we have established
a clinically practical system to predict the therapeutic ef-
fects of three biologics (IFX, TCZ, and ABT). First, we en-
rolled patients with RA who showed inadequate response
to MTX and were administered one of the three biologics
for the first time. Second, we used CDAI to evaluate
therapeutic effects so as to minimize bias among the three
drugs [12, 13]. Third, total RNAs were taken from whole
blood with a well-standardized RNA extraction method
(PAXgene blood RNA system [14]) and analyzed with a
single microarray platform (Agilent Technologies).
There was no overlap of gene sets among the three bio-
logics in GSEA, demonstrating that the molecular targets
of each biologic are distinct. This finding encouraged us
to proceed with this method for comparing other drugs
using this platform.
We observed that NON-REM in the IFX group was typ-
ically reflected in upregulated gene expression patterns of
the inflammasome, which is a multiprotein complex that
plays a key role in the production of inflammatory
cytokines, such as proinflammatory cytokines interleukin
Table 2 Gene Set Enrichment Analysis results
Gene set category Drug Direction of regulation Gene set name Sizea NESb NOM p valuec FDR q valued
Reactome gene sets IFX REM > NON-REM – – – – –
NON-REM > REM Inflammasomes (M1072) 16 1.95 <0.00001 0.07489
TCZ REM > NON-REM – – – – –
NON-REM > REM – – – – –
ABT REM> NON-REM – – – – –
NON-REM > REM Elongation arrest and recovery (M810) 27 1.91 0.00180 0.08880
Regulation of apoptosis (M733) 54 1.96 0.00192 0.09083
Formation of RNA pol II elongation complex (M805) 38 1.85 <0.00001 0.09138
Blood cell gene sets IFX REM > NON-REM – – – – –
NON-REM > REM – – – – –
TCZ REM > NON-REM Specific CD19 (Watkins et al., 2009 [15]) 140 −1.70 0.00602 0.02646
B-cell-induced (Allantaz et al., 2012 [16]) 57 −1.56 0.01603 0.08882
NON-REM > REM – – – – –
ABT REM > NON-REM – – – – –
NON-REM > REM Specific CD56 (Watkins et al., 2009 [15]) 51 1.60 0.02390 0.02615
NK-cell-induced (Allantaz et al., 2012 [16]) 78 1.63 0.00403 0.02861
Abbreviations: IFX infliximab, TCZ tocilizumab, ABT abatacept, REM patients with CDAI remission (defined as CDAI ≤2.8) at 6 months of biologic therapy, NON-REM
patients without CDAI remission at 6 months of biologic therapy, CDAI clinical disease activity index, NK natural killer, RNA pol II RNA polymerase II
A nominal p value <0.05 and false discovery rate q value <0.1 were considered statistically significant
aNumber of genes found in the gene set from the expression dataset
bNormalized enrichment score is the enrichment score for the gene set after it has been normalized across analyzed gene sets
cNominal p value is the statistical significance of the enrichment score. Nominal p value is not adjusted for gene set size or multiple hypothesis testing
dFalse discovery rate is the estimated probability that the normalized enrichment score represents a false-positive finding
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Table 3 Logistic regression analyses using signature scores to predict CDAI nonremission at 6 months of biologic therapy
Drug Gene set Univariate analysis Multivariate analysisa
OR 95 % CI p Value OR 95 % CI p Value
IFX
Inflammasomes 1.81 (1.23–2.78) 0.00382 1.72 (1.14–2.71) 0.00873
TCZ
Specific CD19 (Watkins et al., 2009 [15]) 0.24 (0.05–0.72) 0.02677 0.16 (0.02–0.71) 0.01327
ABT
Elongation arrest and recovery 5.73 (1.47–49.11) 0.04488 6.85 (1.09–4426.71) 0.03309
Specific CD56 (Watkins et al., 2009 [15]) 3.25 (1.18–12.43) 0.04179 6.46 (1.60–88.39) 0.00388
Abbreviations: CDAI clinical disease activity index, IFX infliximab, TCZ tocilizumab, ABT abatacept, OR odds ratio, CI confidence interval, csDMARD conventional
synthetic disease-modifying antirheumatic drug, MTX methotrexate, ESR erythrocyte sedimentation rate
aMultivariate analysis adjusted for significant (p < 0.1) variables as in Additional file 4 (IFX: female, concomitant csDMARD use [except MTX], ESR, CDAI; TCZ: disease
duration, CDAI; ABT: disease duration, concomitant steroid use)
Fig. 2 Comparisons of signature scores between REM and NON-REM for infliximab (IFX) (a), tocilizumab (TCZ) (b, c), and abatacept (ABT) (d–h).
Distributions of the values, mean, and upper and lower limits of 95 % confidence intervals for the mean are shown. p Values were determined
using Student’s t test. p < 0.05 was considered statistically significant. REM patients with CDAI remission (defined as CDAI ≤2.8) at 6 months of bio-
logic therapy, NON-REM patients without CDAI remission at 6 months of biologic therapy, CDAI clinical disease activity index, RNA pol II RNA poly-
merase II, NK natural killer
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(IL)-1β and IL-18 [18]. The inflammasome is associated
with the pathology of various autoimmune diseases, in-
cluding RA [19, 20].
Takeuchi et al. reported that the amount of IFX to ad-
minister to a patient could be indicated by the baseline
TNF protein level to achieve an effective response [21].
Moreover, the inflammasome was reported to be activated
downstream of TNF signaling [22–24]. Therefore, our ob-
servation of upregulated expression of inflammasome-
related genes in the NON-REM group of patients indeed
reflected the stimulated TNF signal, which could not be
attenuated by a standard amount of IFX. As a result,
administering a higher dosage of IFX could be a more
plausible approach. Differential expression of TNF mRNA
between the REM and NON-REM groups was not ob-
served in our analysis, as TNF protein was found mainly
in inflammatory joints rather than in whole blood. In the
future, it would be interesting to delineate the relationship
between expression of inflammasome-related genes and
concentration of TNF in the blood.
For TCZ, we found that a B-cell-related gene set is a
promising predictive signature because patients who had
Fig. 3 Receiver operating characteristic curve analyses for the prediction of CDAI nonremission at 6 months of biologic therapy. a infliximab. b
tocilizumab. c abatacept. CDAI clinical disease activity index, AUC area under the curve, CI confidence interval, PPV positive predictive value, NPV
negative predictive value. “Positive” means CDAI nonremission at 6 months of biologic therapy
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a low expression of B cells had poor remission rates.
TCZ works as an inhibitor of IL-6 receptor signaling by
directly targeting soluble and membrane-bound IL-6 re-
ceptors. IL-6 is an important B-cell-stimulating factor
and induces antibody synthesis [25], and, in RA patho-
genesis, IL-6 induces autoantibody-producing plasma
cells [26]. Furthermore, a subset of B cells, especially
memory B cells, were previously reported to decrease
when TCZ was administered to patients with RA [27, 28].
These findings indicate a close relationship between TCZ
response and B cells, as also pointed out by our results.
The underlying cause differentiating REM and NON-
REM in the TCZ group could be the ability to regulate
the amount of B cells and/or the functional subtypes of
B cells (memory B cells), as reflected by the expression
difference.
NK-cell-related genes were significant predictors of
NON-REM in the ABT group. The expression of NK
cell-related genes was relatively higher in the NON-
REM group than in the REM group. As a component of
the innate immune system, NK cells are known to regu-
late activities of dendritic cells, macrophages and T cells
[29]. For example, NK cells were demonstrated to nega-
tively regulate self-responsive T cells in various auto-
immune disease models [30–32]. A therapy using ABT,
which suppresses T cells, for patients expressing high
levels of NK-cell-related genes, which may render activ-
ities of T cells suppressed, could be redundant. It is more
likely that there are other contributing factors apart
from T cells for this type of patient. However, as pointed
out by Shegarfi et al. [33], the role of NK cells related to
development of RA is worth further delineation.
Core genes found in this study differ from marker
genes identified in other studies (IFX: Lequerré et al.
[2], Tanino et al. [3], Julia et al. [4], Stuhlmüller et al.
[5], Cui et al. [6], and Oswald et al. [34]; TCZ:
Sanayama et al. [7]) due to different evaluation param-
eters of therapeutic outcomes used in each study (e.g.,
Fig. 4 An overview of classification of all 209 samples using 3 signature scores. All 209 samples could be classified into 8 groups, based on the
binary variables derived from the signature scores of the three gene sets (i.e., inflammasome-, specific CD19-, and specific CD56-related). The
threshold for binary call was determined using ROC curve analysis. Top panel: Heat map of 209 samples based on expression patterns of the three
core gene sets. The heat map was performed based on relative expression levels (z-scores) of core genes using TIGR MultiExperiment Viewer
Software (http://www.tm4.org/). Middle panel: Prediction results using signature scores. Patient outcomes were predicted using signature score
and grouped as remission (REM) and nonremission (NON-REM) as indicated in green and red, respectively. Bottom panel: Actual remission status
based on CDAI at 6 months of biologic therapy. In “Individual outcome,” green and red circles represent actual individual cases achieving or not
achieving remission, respectively. In “Rate of NON-REM,” the actual number of cases and the nonremission rates are indicated for all eight groups. REM
patients with CDAI remission at 6 months of biologic therapy, NON-REM patients without CDAI remission at 6 months of biologic therapy, CDAI clinical
disease activity index, IFX infliximab, TCZ tocilizumab, ABT abatacept
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DAS28, EULAR criteria), type of samples used (whole
blood or peripheral blood mononuclear cells), and
sample size. The most important contributing factor
could be the analytical approach. Most biological phe-
nomena, especially development of heterogeneous dis-
eases such as RA, are a consequence not of aberrant
individual genes but rather of a network of related
genes. Therefore, we employed GSEA to capture the
biological feature of genes that would provide a robust
model to predict the efficacy of biologics. In fact, func-
tional gene set analysis was successful in identification
of interferon gene sets as predictors of the efficacy of
rituximab [8, 9].
The performance (i.e., AUCs of ROC curves) of pre-
dicting a therapeutic effect (NON-REM) using the signa-
ture score for each drug (i.e., inflammasomes, specific
CD19, and specific CD56 for IFX, TCZ, and ABT, re-
spectively) were 0.637, 0.796, and 0.768 for IFX, TCZ,
and ABT, respectively. At the optimal cutoff value de-
rived from ROC analysis, a notable feature is the high
PPVs, which were 83.6 %, 92.3 %, and 94.7 % for IFX,
TCZ, and ABT, respectively (Fig. 3). In other words, our
approach has a unique feature that could indicate accur-
ately which patients would not likely achieve remission.
Although it represents an elimination approach rather
than selection of a biologic option, it should be equally
effective at a practical clinical level in the context of
increasing the probability that a patient would achieve
remission. Using this approach, we also discovered a
group of patients (Fig. 4, group 1), constituting about
20 % of patients in this study, who were not likely to
achieve remission with either biologic (remission rate is
a merely 11.9 % [5 of 42]). Future studies exploring
biologics other than the three in the present study or
differentiation analysis to predict achievement of low dis-
ease activity are essential. However, since ROC analysis
was conducted using the same sample group that was
used to construct the gene signatures, an overfitting
problem might occur. It is essential to validate our results
in independent cohorts in the future.
While this was an observational study conducted in an
actual clinical setting, it also inevitably has limitations,
which include bias in clinical background and an un-
matched number of samples collected for the studied bi-
ologics. In fact, IFX was approved long before TCZ and
ABT in Japan, which is self-explanatory why the IFX
group outnumbered the TCZ and ABT groups. We be-
lieve that the choice of actual clinical settings also led
to the bias in clinical background between the three
biologics, such as that the ABT group was older than
the other two and coadministration with MTX was
more likely associated with the IFX group. An inde-
pendent cohort study in which clinical background is
matched could provide a clearer answer. Another
limitation was the significant difference in baseline
clinical background between the REM and NON-REM
groups. Although we have shown that gene expression
signature score remains significant after adjusting the
baseline clinical background, again, the small number
of samples of in the ABT and TCZ groups might not
be absolutely persuasive. We are planning to increase
the number of samples for validation. Last but not
least, as the specimens used in this study contained
RNA extracted from whole blood, which is composed
of various types of blood cells, it is not clear if the
gene expression signatures were just a reflection of
different amounts of components of blood cells. This
remains to be addressed by analyzing immunopheno-
typing data in the future.
Conclusions
We have succeeded in identifying gene expression signa-
tures for prediction of therapeutic effects of three bio-
logics: IFX, TCZ, and ABT. This represents the first
attempt in RA treatment history to address three biologics
in a unified test platform. The signatures also meet the lat-
est clinical notions regarding the mode of action of each
targeted therapy [22, 23, 27, 28]. Therefore, the signatures
should not be limited to predicting therapeutic effects but
should also provide bases for future studies on prediction
of novel drugs as well as a better classification of patients
with RA, thus leading to better care.
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